title: Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.
abstract: OBJECTIVE
  The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC.
  
  
  METHODS
  Patients with unresectable stage IIIB and IV NSCLC (n=43) were treated with CBDCA (AUC 6, day 1), BEV (15 mg/kg, day 1), and PTX (70 mg/m(2), days 1, 8, 15) intravenously every 4 weeks, for 3 to 6 cycles, followed by maintenance BEV (15 mg/kg) every 3 weeks.
  
  
  RESULTS
  The objective response rate and disease control rate were 67.4% and 90.7%, respectively. The median progression-free survival was 7.6 months. The median overall survival was 17.7 months. Common adverse events were tolerable bone marrow suppression, fatigue, hypertension, and nasal bleeding.
  
  
  CONCLUSIONS
  Weekly administration of PTX combined with CBDCA plus BEV therapy was effective, and well-tolerated by advanced NSCLC patients.
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan kubotat@kochi-u.ac.jp.
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kubota
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Okano
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Mizu
authors.initials: M
authors.lastname: Sakai
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Takaoka
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Tsukie
authors.initials: T
authors.lastname: Tsukuda
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Anabuki
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Kawase
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Miyamoto
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohnishi
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
authors.forename: Nobuo
authors.initials: N
authors.lastname: Hatakeyama
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
authors.forename: Hisanori
authors.initials: H
authors.lastname: Machida
authors.affiliation: Division of Respiratory Medicine, Kochi Health Sciences Center, Kochi, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Urata
authors.affiliation: Division of Respiratory Surgery, Chikamori Hospital, Kochi, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Yamamoto
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Ogushi
authors.affiliation: Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Kochi, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Yokoyama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
keywords: Non-small cell lung cancer; bevacizumab; carboplatin; first-line; weekly-paclitaxel